Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Ascendis Pharma A/S (ASND)

270 + Investors. Track Smart Money conviction in ASND. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↓ -36
Streak
1Q ▼
Buyers last Q
47%

Smart Money Signals — ASND

Based on 270 hedge funds · latest filing: 2026 Q1 · updated quarterly

📉

Selling streak — 1 quarter in a row

last 6Q
For 1 consecutive quarter, more hedge funds reduced or closed their ASND positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.
📊

High ownership — 88% of 3.0Y peak

88% of all-time peak
270 funds currently hold this stock — 88% of the 3.0-year high of 306 funds (reached 2025 Q4). Ownership is elevated but not yet at maximum concentration. Room to grow, but watch if the trend reverses.
📶

Steady growth — +12% more funds vs a year ago

fund count last 6Q
+28 new funds entered over the past year (+12% YoY). Gradual, steady growth in institutional ownership is generally a healthy signal — not a speculative rush, but consistent conviction.
🟠

More sellers than buyers — 47% buying

153 buying174 selling
Last quarter: 174 funds reduced or exited vs 153 that bought or added. When more than half of active funds are selling, it's a caution flag — especially if the stock price hasn't moved down yet.
⚠️

Fewer new buyers each quarter (-24 vs last Q)

new funds entering per quarter
Funds opening this position for the first time: 44 → 62 → 58 → 34. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.
🔒

50% of holders stayed for 2+ years

■ 50% conviction (2yr+) ■ 28% medium ■ 22% new
135 out of 270 hedge funds have held ASND for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
➡️

Steady discovery — ~34 new funds/quarter

51 → 44 → 62 → 58 → 34 new funds/Q
New funds entering each quarter: 44 → 62 → 58 → 34. Consistent flow of new institutional buyers without clear acceleration or slowdown.
🏛️

Deep conviction — 60% of holders stayed 2+ years

■ 60% veterans ■ 10% 1-2yr ■ 31% new
Of 288 current holders: 172 (60%) have held for over 2 years without selling. These are not momentum buyers — they have lived through drawdowns and stayed. A large veteran base acts as a stabilizing force during selloffs.
✅

Strong quality — 38% AUM from major funds

38% from top-100 AUM funds
48 of 270 holders rank in the top 100 by AUM, accounting for 38% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.
3.3
out of 10
Low Exit Risk
Exit risk score 3.3/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — ASND

In 2026 Q1, 153 hedge funds were net buyers of ASND (34 opened a new position, 119 added to an existing one), while 174 reduced or exited (104 trimmed, 70 sold completely) — a 47% buyer ratio, indicating roughly balanced activity. 38% of total institutional value in ASND is held by top-100 AUM funds, reflecting strong institutional quality. Net fund flow last quarter: -36 funds (more exits than new entries). Total institutional holders: 270.

Hedge Fund Ownership: ASND

How many hedge funds hold ASND — quarterly history vs. share price
Quarterly hedge fund ownership of ASND vs. share price

Market Analysis: ASND

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: ASND

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Ascendis Pharma A/S (ASND) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much ASND has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 78d ago
ASND
-2.4%
XLV
+2.8%

ASND outperformed XLV by -5.2% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 33d ago
ASND
-7.2%
XLV
+3.9%

Since the filing became public, ASND outperformed XLV by -11.1% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

21 top-rated funds 8 high-conviction
Consensus
5.8
/ 10
breadth
×
Elite
4.5
/ 10
conviction
Hedge Fund Positioning: ASND
270 + Investors

Track Smart Money conviction in ASND. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 270 306 -11.76%
13F Shares 55M 65M -15.06%
Total Value $12.58B $13.53B -7.03%
New Positions 34 58 -24
Increased Positions 109 127 -18
Closed Positions 70 40 +30
Reduced Positions 103 92 +11
Total Calls 15 16 -6.25%
Total Puts 10 8 25.0%
PUT/CALL Ratio 0.67 0.5 Bullish

Statistics: ASND

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

270 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in ASND. Verified SEC 13F-HR filings.

QUARTER:
Top 25 ASND holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Ra Capital Management, L.P. 24.92% 10,281,496 $2.35B
2 Resolute Capital Asset Partners LLC 11.87% 98,627 $22.6M
3 Avoro Capital Advisors LLC 11.39% 5,062,500 $1.16B
4 Tri Locum Partners LP 8.20% 255,332 $58.4M
5 Perceptive Advisors LLC 6.85% 1,531,421 $350.3M
6 Catalio Capital Management, LP 6.17% 129,111 $29.5M
7 Westfield Capital Management Co LP 4.62% 4,813,440 $1.10B
8 Eagle Health Investments LP 3.47% 86,650 $19.8M
9 PFM Health Sciences, LP 3.17% 152,034 $34.8M
10 Silverarc Capital Management, LLC 2.91% 124,658 $28.5M
11 Rock Springs Capital Management LP 2.62% 194,000 $44.4M
12 Nan Fung Group Holdings Ltd 2.57% 13,600 $3.1M
13 Matisse Capital 2.54% 26,077 $6.0M
14 ARS Investment Partners, LLC 2.49% 209,456 $47.9M
15 Arrowpoint Investment Partners (Singapore) Pte. Ltd. 2.40% 11,828 $2.7M
16 Vestal Point Capital, LP 2.40% 375,000 $85.8M
17 First Turn Management, LLC 1.95% 76,300 $17.5M
18 Rice Hall James & Associates, LLC 1.89% 148,386 $33.9M
19 Synergy Asset Management, LLC 1.71% 70,456 $16.1M
20 Defilade Capital Management, L.P. 1.67% 51,895 $11.9M
21 Troluce Capital Advisors LLC 1.40% 99,600 $22.8M
22 Quantedge Capital Pte Ltd 1.38% 11,000 $2.5M
23 Integral Health Asset Management, LLC 1.26% 115,000 $26.3M
24 Henry James International Management Inc. 1.22% 14,784 $3.4M
25 DAFNA Capital Management LLC 1.21% 23,177 $5.3M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Ascendis Pharma A/S (ASND)

What does the Smart Money Trend signal show for ASND?

Selling streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds reduced or closed their ASND positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

What is the institutional breadth score for ASND?

More sellers than buyers — 47% buying: Last quarter: 174 funds reduced or exited vs 153 that bought or added. When more than half of active funds are selling, it's a caution flag — especially if the stock price hasn't moved down yet.

What is the fund quality score for ASND holders?

Strong quality — 38% AUM from major funds: 48 of 270 holders rank in the top 100 by AUM, accounting for 38% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held ASND?

50% of holders stayed for 2+ years: 135 out of 270 hedge funds have held ASND for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Ascendis Pharma A/S (ASND) following the 2026 Q1 hedge fund 13F filings?

As of today, ASND has moved -7.2% since the 2026 Q1 13F filing date (May 15, 2026), compared to +3.9% for the XLV sector ETF — an outperformance of -11.1%. Since the quarter end (March 31, 2026), ASND has gained -2.4% vs +2.8% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →